Clinical trial
A Study to Look at the Efficacy and Safety of Keppra® Extended Release…
NCT00368069 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00368069 |
|---|---|
| Title | A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR |
| Official title | A Double-blind, Placebo-controlled, Randomized Efficacy and Safety Study of Keppra® Extended Release Formulation - XR Once Daily as add-on Therapy in Subjects From 12 to 70 Years With Refractory Epilepsy Suffering From Partial Onset Seizures. |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Epilepsy |
| Intervention type | Drug |
| Interventions | Keppra® extended release formulation - XR, Placebo |
| Enrollment | 158 |
| Start date | Aug 1, 2006 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Aug 24, 2006 |
| Last update posted | Jul 15, 2020 |
| Countries | Brazil, Finland, India, Mexico, Russia, South Africa, Ukraine |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: